ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
The Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Children.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Do we need to vaccinate every child against COVID-19: What evidence suggests-A systematic review of opinions.Frontiers in public health · 2022Pooled it
- Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial.Human vaccines & immunotherapeutics · 2024Trial
- Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.Vaccine · 2023Trial
- Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.Frontiers in immunology · 2022Trial
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.The Lancet. Infectious diseases · 2021Trial
- Article
- Factors Associated with Adverse Outcomes among SARS-CoV-2 Positive Children in a Tertiary Government COVID-19 Referral Hospital in the Philippines.Acta medica Philippina · 2024Article
- Emergency Departments: An Underutilized Resource for Expanding COVID-19 Vaccine Coverage in Children.Vaccines · 2023Article
- Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.Vaccine · 2023Article
- Variables Associated With COVID-19 Vaccination Among Israeli Adolescents and the Need for Targeted Interventions.The Pediatric infectious disease journal · 2022Article
- Clinician perspectives on pediatric COVID-19 vaccination: A qualitative study in central and western, Massachusetts.Preventive medicine reports · 2022Article
- Article
- COVID-19 in children: epidemic issues and candidate vaccines.Chinese medical journal · 2022Review
- Strategies and safety considerations of booster vaccination in COVID-19.Bosnian journal of basic medical sciences · 2022Review
- Providing children with COVID-19 vaccinations is challenging due to lack of data and wide-ranging parental acceptance.Acta paediatrica (Oslo, Norway : 1992) · 2022Review
- Parental Willingness to Vaccinate Their Children Against SARS-CoV-2 in Jordan: An Explanatory Cross-Sectional Study.Risk management and healthcare policy · 2022Article
- Safety & effectiveness of COVID-19 vaccines: A narrative review.The Indian journal of medical research · 2022Review
- Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years.Frontiers in public health · 2022Article
- COVID-19 in children and the importance of COVID-19 vaccination.World journal of pediatrics : WJP · 2021Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the role of children in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be defined, children likely play an important role based on our knowledge of other respiratory viruses. Children are more likely to be asymptomatic or have milder symptoms and less likely to present for healthcare and be tested for SARS-CoV-2. Thus, our current estimates are likely under-representative of the true burden of SARS-CoV-2 in children. Given the potential direct benefit of a SARS-CoV-2 vaccine in children and the substantial indirect benefit through community protection, or "herd immunity," we argue that planning and implementation of SARS-CoV-2 vaccines should include children. Furthermore, community protection occurred after widespread implementation of prior childhood vaccines against Streptococcus pneumoniae, rubella, and rotavirus. We detail considerations for vaccine clinical trials, potential barriers to the implementation of widespread vaccination and argue why children would be an ideal target population for vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.